These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 16508590

  • 1. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.
    Haller H, Viberti GC, Mimran A, Remuzzi G, Rabelink AJ, Ritz E, Rump LC, Ruilope LM, Katayama S, Ito S, Izzo JL, Januszewicz A.
    J Hypertens; 2006 Feb; 24(2):403-8. PubMed ID: 16508590
    [Abstract] [Full Text] [Related]

  • 2. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H, Kim-Mitsuyama S, Jinnouchi T, Matsui K, Arakawa K.
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [Abstract] [Full Text] [Related]

  • 3. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.
    Haller H, Ito S, Izzo JL, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G, ROADMAP Trial Investigators.
    N Engl J Med; 2011 Mar 10; 364(10):907-17. PubMed ID: 21388309
    [Abstract] [Full Text] [Related]

  • 4. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
    Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Ghadanfar M, Weissbach N, Xiang Z, Armbrecht J, Pfeffer MA.
    Nephrol Dial Transplant; 2009 May 10; 24(5):1663-71. PubMed ID: 19145003
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: A randomized controlled trial.
    Agha A, Amer W, Anwar E, Bashir K.
    Saudi J Kidney Dis Transpl; 2009 May 10; 20(3):429-35. PubMed ID: 19414946
    [Abstract] [Full Text] [Related]

  • 9. Office and ambulatory pulse pressure--association with clinical characteristics and cardiovascular risk factors in normoalbuminuric patients with type 2 diabetes (ROADMAP study).
    Januszewicz A, Ritz E, Viberti G, Mimran A, Rabelink AJ, Rump LC, Ruilope LM, Katayama S, Ito S, Izzo JL, Haller H.
    J Hum Hypertens; 2011 Nov 10; 25(11):679-85. PubMed ID: 21150933
    [Abstract] [Full Text] [Related]

  • 10. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
    Hughes DB, Britton ML.
    Pharmacotherapy; 2005 Nov 10; 25(11):1602-20. PubMed ID: 16232022
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Preemptive olmesartan for the delay or prevention of microalbuminuria in diabetes.
    Ingelfinger JR.
    N Engl J Med; 2011 Mar 10; 364(10):970-1. PubMed ID: 21388316
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Effect of lisinopril on progression of retinopathy and microalbuminuria in normotensive subjects with insulin-dependent diabetes mellitus].
    Sjølie AK, Chaturvedi N, Fuller J.
    Ugeskr Laeger; 1999 Feb 15; 161(7):949-52. PubMed ID: 10051804
    [Abstract] [Full Text] [Related]

  • 15. Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes.
    Estacio RO, Coll JR, Tran ZV, Schrier RW.
    Am J Hypertens; 2006 Dec 15; 19(12):1241-8. PubMed ID: 17161769
    [Abstract] [Full Text] [Related]

  • 16. [The role of angiotensin II AT1-receptor antagonists in renal and cardiac protection in type-2 diabetes mellitus].
    Ravera M, Deferrari L, Ratto E, Vettoretti S, Parodi D, Deferrari G.
    Ital Heart J Suppl; 2003 Mar 15; 4(3):210-6. PubMed ID: 12784755
    [Abstract] [Full Text] [Related]

  • 17. Rationale for and study design of the sulodexide trials in Type 2 diabetic, hypertensive patients with microalbuminuria or overt nephropathy.
    Lambers Heerspink HJ, Fowler MJ, Volgi J, Reutens AT, Klein I, Herskovits TA, Packham DK, Fraser IR, Schwartz SL, Abaterusso C, Lewis J, Collaborative Study Group.
    Diabet Med; 2007 Nov 15; 24(11):1290-5. PubMed ID: 17956455
    [Abstract] [Full Text] [Related]

  • 18. [Primary cardiorenal prevention in patients with type-2 diabetes. The Roadmap study].
    Halimi S.
    Presse Med; 2005 Oct 22; 34(18):1300-2. PubMed ID: 16269993
    [Abstract] [Full Text] [Related]

  • 19. The angiotensin-II (AT-II) receptor blocker olmesartan reduces renal damage in animal models of hypertension and diabetes.
    Pugsley MK.
    Proc West Pharmacol Soc; 2005 Oct 22; 48():35-8. PubMed ID: 16416656
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.